This has been one of those weeks where I spent some time thinking about taking risks in science. How much risk one should take? Risks can come in many forms. It could be at the core level at the bench doing specific experiments and not others. There’s risk in clinical trials, and even in advocacy. Sometimes […]
Weekly science reads: Macchiarini trial, somites, CRISPR babies Read More »
The fact that a person for the first time has received a heart transplant from a pig and it was a genetically modified pig made big news this week. Organ transplant waiting lists are a huge problem so if this kind of approach can be proven to be safe and effective, it would be a
Recommended reads: pig heart transplant, lasers, $11K pub fee Read More »
The amount of biomedical science hype out there is mindboggling at times, but some media or other items really take the cake for being exceptionally bad. Today’s post highlights the worst of the year 2021 as the candidates for my annual The Screamers science hype award. Click on the link in the previous sentence to
What if you could get 8-year grants to do whatever biomedical research you wanted? This sounds like a dream for many of us in the life sciences, but the first news item this week is all about such a potential new funding approach. The item especially caught my eye as I’m going to be doing
Weekly reads: hydra heads, iblastoids, new 8-year grants Read More »
Stem cell clinic firms often come and go rather quickly, but a few like Regenexx have persisted. It’s even become a brand name. I’ve been writing here on The Niche for more than twelve years about stem cell clinics. Regenexx has been around that whole time. Along with its founder Dr. Chris Centeno. Patients have
Fact-checking Regenexx: reviews, data & cost Read More »
Anyone with a seemingly only semi-functional nervous system now post-election might be turning to science to help their brains bounce back. Here are some of the things I’ve been reading or hope to soon. In good news for the stem cell and regenerative medicine field, especially here in California, it looks like us California voters
What do a Panama stem cell clinic and the Duke Autism Center have in common? More than I might have imagined. It’s a remarkable story that needs telling. Duke Autism Center There is a puzzle when it comes to the controversial idea of using cord blood for autism. Why? Because two of the strongest proponents
Duke Autism Center has Panama clinic to thank for $10s millions? Read More »
What are you reading these days and does it include topics like cell therapies for COVID-19, ALS, regenerative potential of fibroblasts, and why Zoom meetings are so tiring for the brain? I cover those topics and more below with recommended reads including papers and media items. Here’s last week’s recommended reads. Here’s to fibroblasts, which
Weekend recommended reads: Athersys, ALS, COVID-19, Fibroblasts, Zoom brain Read More »
“HSCT Chicago Clinic Closing!” is the startling header in all caps on a patient-run Facebook page about a stem cell therapy clinical trial program at Northwestern University. What’s going on? Unfortunately, the promising field of hematopoietic stem cell transplantation (HSCT) for multiple sclerosis (MS) and other autoimmune diseases seems to have suffered an unexpected setback
Northwestern abruptly ending Burt HSCT autoimmune trials Read More »
Magenta Therapeutics is a biotech company with a portfolio including stem cell products. Their most well known investigational drug product is an expanded umbilical cord stem cell product called MGTA-456, an “ex-Novartis” product. Magenta just released new trial data on MGTA-456, which I see as a case of good news-bad news, and investors seem to
Magenta Therapeutics Good News-Bad News Trial Data Read More »